Lexaria Bioscience Corp. LXRP Archives - Page 11 of 27

TuesdayMar 12, 2019 1:30 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Aims to Conduct Further Human Clinical Trials Following Positive TurboCBD Results

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) plans to conduct additional clinical trials using DehydraTECH(TM) in CBD after recently reporting noteworthy results of cardiovascular performance improvements with TurboCBD. A recent article discussing the company reads, “TurboCBD is Lexaria’s proprietary DehydraTECH-powered, CBD-fortified hemp-oil capsule. The capsules are formulated with full-spectrum hemp oil, ginseng and ginkgo for enhanced focus and memory. They are marketed as a mental and physical boost aimed at helping to remove brain fog, fatigue and stress. TurboCBD is molecularly engineered for quick and high absorption rates into the circulatory system. . . . In a recent press release (http://ibn.fm/OwOtT),…

TuesdayMar 12, 2019 12:28 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Innovating on Numerous Fronts with DehydraTECH Drug Delivery Platform

Lexaria Bioscience is focusing on its unique technology for the delivery of bioactive compounds The company’s concentration on oral ingestion results in an option that often healthier than other delivery methods Its DehydraTECH technology has potential applications for nicotine absorption Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) focuses on technology for the improved delivery of bioactive compounds. Its DehydraTECH drug delivery platform fosters healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules. The company’s process changes the way edible cannabinoids enter the body (http://ibn.fm/CB41E). A drug delivery innovator, Lexaria Bioscience is headquartered in Kelowna,…

MondayMar 04, 2019 12:46 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) to Conduct Clinical Studies on Oral Nicotine Delivery Utilizing DehydraTECH Absorption Platform

Lexaria Nicotine LLC, a subsidiary of Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), recently secured research and development (“R&D”) funding in exchange for equity and licensing rights. Utilizing its DehydraTECH absorption platform, Lexaria will execute a wide-ranging series of clinical studies on oral forms of nicotine delivery. A recent article discussing the company reads, “Under an investment agreement by its wholly owned subsidiary, Lexaria Nicotine LLC, a partner, will provide $1 million toward research on nicotine consumer products that use DehydraTECH(TM) (http://ibn.fm/9JkL7). . . . Lexaria’s partner will receive certain licensing rights to commercialize these DehydraTECH products exclusively in the United…

TuesdayFeb 26, 2019 9:33 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Supports Recent FDA Statement on Novel Nicotine Replacement Therapies

Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) this morning conveyed its support for the Food & Drug Administration’s (“FDA”) February 21 statement titled “Smoking Cessation and Related Indications: Developing Nicotine Replacement Therapy Drug Products”. The FDA’s statement outlined the development of safe and effective novel nicotine replacement therapies to help smokers quit cigarettes, stating that “novel products with different characteristics or routes of nicotine delivery have the potential to offer additional opportunities for health-concerned smokers interested in quitting.” Lexaria recently entered a partnership with a leading tobacco company to use DehydraTECH(TM) technology to develop…

MondayFeb 25, 2019 12:50 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Plans Additional Clinical Trials Following Successful Tests

Company recently announced significant findings of cardiovascular performance improvements with TurboCBD Lexaria plans additional human clinical trials of CBD Company is now moving forward with clinical studies on oral forms of nicotine delivery following a large investment agreement Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is a food bioscience company that developed and commercialized cost-effective drug delivery platform DehydraTECH. This technology enhances the performance of beneficial compounds in ingestible products. Currently, Lexaria has patents pending worldwide for use of the technology in a range of bioactive molecules, including cannabinoids, nicotine, NSAID pain relievers and more. Leveraging this platform, the taste,…

ThursdayFeb 21, 2019 10:08 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Releases Additional Significant Findings of its DehydraTECH(TM) Powered TurboCBD(TM) Capsules

Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) today announced additional significant findings of TurboCBD(TM), the company's proprietary, DehydraTECH(TM) powered, cannabidiol (''CBD'') fortified hemp-oil capsule upon completion of further data analyses from its 2018 randomized, placebo-controlled, double-blinded European human clinical study. According to the update, a single 90mg dose of TurboCBD as compared to the same dose of generic CBD provided evidence of lower blood pressure, higher blood flow to the brain, faster delivery onset and larger quantities of CBD into the bloodstream. The study revealed key metabolic and hemodynamic performance findings linked to bioavailability…

FridayFeb 15, 2019 1:22 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Subsidiaries Work to Secure New Deals for DehydraTECH in Various Industries

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) is finding success through its ability to form subsidiaries specializing in the use of its patented drug-delivery platform, DehydraTECH. A recent article discussing the company reads, “DehydraTECH is a drug-delivery platform patented for cannabidiol and all other nonpsychoactive cannabinoids, as well as THC (tetrahydrocannabinol) and psychoactive cannabinoids. The technology is an enabling platform that works across multiple industries, thereby providing a large base of consumers with healthier forms of consumption than lighting up. . . . LXRP and DehydraTECH stand out among the competition. The company has a total of 10 patents issued with…

WednesdayFeb 13, 2019 11:04 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) to Execute Clinical Studies on Oral Forms of Nicotine Delivery Using DehydraTECH

LXRP’s DehydraTECH research funded by a partner that will provide $1 million, with an option for millions more LXRP subsidiary Lexaria Nicotine LLC recently entered a definitive investment agreement to receive R&D funding in exchange for equity and licensing rights In exchange, partner received minority equity interest in the subsidiary Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) will conduct a comprehensive series of clinical studies on oral forms of nicotine delivery utilizing its DehydraTECH absorption platform. Under an investment agreement by its wholly owned subsidiary, Lexaria Nicotine LLC, a partner will provide $1 million toward research on nicotine consumer products…

MondayFeb 11, 2019 11:19 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Creates Unique Opportunity in Global Cannabis Industry

Big corporations are investing in the cannabis industry Major tobacco company provides financing for LXRP LXRP boasts revenue streams within the nicotine industry and opportunity in other sectors Lexaria is a unique company doing business on its own terms The cannabis industry is experiencing impressive growth thanks to both legal and social changes worldwide, and big corporations are stepping up to invest. In a new Audio Press Release (“APR”), CannabisNewsAudio praised Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) (http://ibn.fm/sR2IL) for building a large funding deal on its own terms. The APR, ‘Outside Investment, New Technology Support Growing Cannabis Industry’, highlighted Lexaria’s…

ThursdayFeb 07, 2019 2:16 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Subsidiary Secures Key R&D Funding for Oral Nicotine Delivery Using DehydraTECH Technology

Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) wholly owned subsidiary, Lexaria Nicotine LLC, recently struck a deal with a large tobacco partner, securing significant R&D financing for the company’s DehydraTECH absorption platform (http://ibn.fm/Kx7Cm). A recent article discussing the company reads, “Through the agreement, the partner also has the option to provide up to $11 million in additional research through multiple phased private financings to underwrite LXRP’s R&D. In exchange, the partner will receive certain license rights to commercialize these DehydraTECH products exclusively in the United States and non-exclusively elsewhere. The partner, the largest cigarette company in the U.S., will be obligated…

Site Search

Company Search

Tag: Lexaria Bioscience Corp. LXRP